我们课题组致力于开拓新的方法用于研究人类化学生物学及推动药物的发现。我们结合尖端的药物化学和新兴化学蛋白质组学推进我们对疾病的认识和发现新的治疗药物。最初的成果包括：被誉为 “突破”的首创新药已批准在美国和欧盟上市，以及人类样品中活细胞成像和应用的小分子探针。
对于人类的多种类型的肿瘤疾病，大量生物数据证明，非正常的激酶活性在这些疾病中异常活跃。因此，我们的药物化学方向更关注于这类关键的药物靶标。我们正在开发多种结合形式靶向激酶催化结构域与和实施针对激酶的其他结构域新的化合物。
2) 激酶组学 -研究信号的转导精密工具
细胞的活性很大程度受生物及化学信号的影响。激酶是信号转导通路的主要的调控因素。我们的主要目标是能够直接在人类活细胞的内源性环境中检测激酶的活性。我们正在开发新型活性/亲和力的探针激酶和方法来捕获这些酶的生理底物，了解细胞环路中时间和空间的控制因素。
3) 发展合成方法学
众多科研基础中其中之一是有机合成。尽管这个领域已具有惊人的进步，但仍然有很大的需求取发现新的方法来提供方便的临床相关的生物活性分子。
1) Ding, N.; Li, X.; Shi, Y.; Ping, L.; Wu, L.; Fu, K.; Feng, L.; Zheng, X.; Song, Y.*;Pan, Z. *; Zhu, J.* “Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.”Oncotarget2015, published online Apr 14.
2) Zhang Q, Liu H,Pan Z.*“A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells”Chem. Commun.2014,50, 15319.
3) Liu H, Yang Z,Pan Z.*“Synthesis of Highly Substituted Imidazolidine-2,4-dione (Hydantoin) through Tf2O-Mediated Dual Activation of Boc-Protected Dipeptidyl Compounds”Org. Lett.2014,16, 5902.
4) Zhou Y, Guo T, Tang G, Wu H, Wong N-K,Pan Z.*“Site-selective Protein Immobilization by Covalent Modification of GST Fusion Proteins”Bioconjugate Chem.2014,25, 1911.
5) Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N,Pan Z.*“Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity”J. Med. Chem.2014,57, 5112.
6) Zhou Y, Guo T, Li X, Dong Y, Galatsis P, Johnson D S,Pan Z.*“Discovery of selective 2,4-diaminopyrimidinebased photoaffinity probes for glyoxalase I”Med. Chem. Commun.2014,5, 352. (Invited for the thematic issue on “Chemical biology for target identification and validation”)
7) Zheng J, Lin S, Zhu X, Jiang B*, Yang Z*,Pan Z.*“Reductant-directed formation of PS-PAMAM-supported gold nanoparticles for use as highly active and recyclable catalysts for the aerobic oxidation of alcohols and the homocoupling of phenylboronic acids.”Chem. Commun.2012,48,6235.
8) Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.;Pan, Z.;Thamm, D.H.; Miller, R.A.; Buggy, J.J. “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and Is Efficacious in Models of Autoimmune Disease and B-cell Malignancy”Proc. Natl. Acad. Sci. USA2010,107,13075.
9) Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Peter R. Young, Dalrymple, S. A. and Palmer, J. T. “Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase”ChemMedChem2007,15:58. (corresponding author)
10) Pan, Z.; Jeffery, D. A.; Chehade, K.; Beltman, J.; Clark, J. M.; Grothaus, P. G.; Bogyo, M. and Baruch, A. “Development of Activity-based Probes for Trypsin-family Serine Proteases”Bioorg. Med. Chem. Lett.2006,16: 2882. (co-corresponding author)
